|
WO2010105193A1
|
|
Method and assays for quantitation of acetamide in a composition
|
|
US2010063583A1
|
|
Use of soluble epoxide hydrolase inhibitors in the treatment of inflammatory vascular diseases
|
|
US2009270452A1
|
|
Use of soluble epoxide hydrolase inhibitors in the treatment of smooth muscle disorders
|
|
TW200946118A
|
|
Soluble epoxide hydrolase inhibitors
|
|
TW201033203A
|
|
Soluble epoxide hydrolase inhibitors
|
|
WO2009086429A1
|
|
Soluble epoxide hydrolase inhibitors
|
|
US2009247521A1
|
|
Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction
|
|
US2009197916A1
|
|
Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders
|
|
US2009082350A1
|
|
Soluble epoxide hydrolase inhibitors
|
|
TW200930359A
|
|
Soluble epoxide hydrolase inhibitors
|
|
WO2009035951A2
|
|
Soluble epoxide hydrolase inhibitors
|
|
WO2009035928A1
|
|
Soluble epoxide hydrolase inhibitors
|
|
US2009023731A1
|
|
Soluble epoxide hydrolase inhibitors
|
|
TW200838851A
|
|
Processes for the preparation of piperidinyl-substituted urea compounds
|
|
US2008221105A1
|
|
Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders
|
|
EP2077839A2
|
|
Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis
|
|
US2008200467A1
|
|
Soluble epoxide hydrolase inhibitors
|
|
EP2081898A2
|
|
Adamantylurea compounds as soluble epoxide hydrolase inhibitors
|
|
CN101535259A
|
|
Phenylurea compounds as soluble epoxide hydrolase inhibitors
|
|
MX2009009754A
|
|
4 -pi peridinylurea compounds as soluble epoxide hydrolase inhibitors.
|
